General Characteristics
| Age: | <20 years |
| Gender: | Male |
| Disease Origin: | Clival |
| Disease Status: | Recurrent, Metastatic |
| Metastatic Site(s): | N/A |
| Sample Origin: | Clivus |
| Prior Radiation: | No |
| Prior Systemic Therapy: | No |
| Source: | Dr. Mark Prince and John Henry Owen University of Michigan |
| Notes: | The UM-Chor5 series is a progression model from the same patient; UM-Chor5C is derived from a local recurrence of the tumor that yielded UM-Chor5. This cell line was developed from the same tumor sample as the CF555 PDX model. |
Molecular Features
| Cell Morphology: | Physaliferous |
| TBXT Expression: | Positive; 5x that of U-CH2 |
| TBXT Localization: | Nuclear |
| CD24 Expression: | Positive; 1x that of U-CH2 |
| HLA Type: | |
| Sequence Data: | WES and transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions. |
| SMARCB1 Status: | Truncating mutation (Lys16*) |
| Validation Results: | Validation Report |
Growth Conditions
| Growth Medium: | IMDM: RPMI-1640 (4:1) +10% FBS |
| Freeze Medium: | 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO |
| Culture Conditions: | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| Subculturing Instructions: | Cell Culture Procedures |
Publications
Characterized By:
|